Page last updated: 2024-10-31

nafamostat and Hepatitis B

nafamostat has been researched along with Hepatitis B in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Inoue, K1
Yoshiba, M1

Reviews

1 review available for nafamostat and Hepatitis B

ArticleYear
[Blood purification for patients with chronic renal failure accompanied by severe liver disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 6

    Topics: Acute Disease; Anticoagulants; Benzamidines; Carrier State; Cellulose; Chronic Disease; Dialysis Sol

2004